At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 19 enrolled
Drug / intervention
selumetinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of AZD6244 in Advanced or Metastatic Hepatocellular Carcinoma
In Brief
A Phase 2 clinical trial evaluating selumetinib and pharmacological study for Adult Primary Hepatocellular Carcinoma and 3 related conditions. Completed, enrolled 19 participants across 6 sites.
Detailed Summary
This phase II trial is studying selumetinib to see how well it works in treating patients with locally advanced or metastatic liver cancer. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2007
First PostedJan 2008
Primary CompletionJun 2012
TodayJul 2026
First PostedJan 30, 2008
Enrollment StartNov 1, 2007
Primary CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 18.4 years ago
Interventions
selumetinibdrug
Given orally
pharmacological studyother